HomeAI · summaries
Storia in 3 fonti
FDA's acting director of cell and gene therapies to leave position
Vijay Kumar, FDA's acting OTP director, says he's stepping down for reasons unrelated to agency turmoil, as the White House also weighs finalists for FDA commissioner.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
statnews.com
FDA’s top gene therapy regulator is leaving his role
The departure of Vijay Kumar follows a broader leadership shakeup at the FDA.
- ·
biopharmadive.com
Top FDA gene and cell therapy regulator to step down
Following Vijay Kumar’s exit, acting CBER Director Karim Mikhail will also oversee a review office that has become a battleground for debates on FDA flexibility.
- ·
endpoints.news
FDA's acting director of cell and gene therapies to leave position
Vijay Kumar, FDA's acting OTP director, says he's stepping down for reasons unrelated to agency turmoil, as the White House also weighs finalists for FDA commissioner.